TREATMENT WITH AUTOLOGOUS STEM CELLS TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS-10 YEARS SINGLE CENTER EXPERIENCE
Abstract
background-multiple myeloma is a malignant neoplasm of plasma cells. Autologous stem cells transplantation (ASCT) has become the first line of therapy mainly because of the low transplant-related mortality and prolongation of event free survival resulting in improved quality of life. High–dose therapy (HDT) with ASCT should be part of primary treatment in newly diagnosed patients up to the age of 65 years with adequate performance status and organ function. Aim: the aim of this study is to present our ten years experience in treatment of patients with multiple myeloma with ASCT. Material and methods: during a 10- years period we have performed 35 courses of HDT and consecutive ASCT in 31 patients with multiple myeloma (4 tandem transplantation). In this study we retrospectively analyzed the epidemiological characteristics of this group of patients. Results: Female:14 Male:17 Median age: 52 years (from 43-64). High-dose Melphalan in doses 200mg/m2 was used as conditioning regimen, in second (tandem) transplantation 140mg/m2. Median count of infused CD34+ cells was 3,65x108/kg. As a source of added stem cells we use phlebothomy in 3 patients. The median period from diagnosis to transplantations was 10 months. Of 31 patients, 21 (67%) are alive, 10 (33%) are have died (3 renal failure, 3 multi-organ failure, 2 infections, 2 fatal cerebral bleeding). The disease-free survival was 24 months. OS was 50 months and EFS was 38 months. Conclusions: ASCT offer better results in survival and quality of life compared with patients treated only with standard chemotherapy.
References
Attal M, Harousseau JL, Stoppa AM, et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335:1844–1845.
Child JA, Morgan GJ, Davies FC, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875–1883.
Palumbo A, Bringhen S, Petrucci MT, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood. 2004;104:3052–3057.
Fermand JP, Katsahian S, Divine M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol. 2005;23:9227–9233.
Blade J, Rosinol L, Sureda A, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood. 2005;106:3755–3759.
Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of the phase III US Intergroup trial S4321. J Clin Oncol. 2006;24:929–936.
Moreau P, Facon T, Attal M, et al. Comparison of 200 mg/m2 melphalan and 8Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma. Final analysis of the IFM95-02 randomized trial. Blood 2002;99:731–735
Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplant for newly diagnosed multiple myeloma. Blood. 1999;93:55–65.
Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem cell transplantation for multiple myeloma. N Engl J Med. 2003;349:2495–2502.
Cavo M, Zamagni E, Cellini C, et al. Single versus tandem autologous transplants in multiple myeloma: Italian experience. J Clin Oncol 2007;25:2434–2441.
Fermand JP. Single versus double high-dose therapy supported with autologous blood stem cell transplantation using unselected or CD34 enriched ABSC: results of a two by two designed randomized trial in 230 young patients with multiple myeloma [abstract]. Hematol J. 2005;90:40.
Sonneveld P, Van Der Holt B, Sergeren CM, et al. Intensive versus double intensive therapy in untreated multiple myeloma. Updated analysis of the prospective phase III study Hovon 24-MM [abstract]. Hematol J. 2005;90:37–38.
Goldschmidt H. Single versus double high-dose therapy in multiple myeloma: second analysis of the trial GMMG-HD2 [abstract]. Hematol J. 2005;90:38.
Greipp PR, San Miguel JS, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–3420
Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood. 2007;109:3489–3495.
Shaughnessy JD, Zhan F, Burrington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109:2276–2284.
Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone as primary therapy in preparation for autologous transplantation for myeloma. Blood. 2005;106:35–39.
Macro M, Divine M, Uzunhan Y, et al. Dexamethasone plus Thalidomide compared to VAD as a pre-transplant treatment in newly diagnosed multiple myeloma [abstract]. Blood. 2006;108:Abstract no. 57.
Rajkumar SV, Blood E, Vesole D, et al. Phase III trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma. J Clin Oncol. 2006;24:431–436.
Goldschmidt H, Sonneveld P, Breitkreuz I, et al. Phase III study on the effect of thalidomide combined with high-dose melphalan in myeloma patients up to the age of 65 years [abstract]. Blood. 2005;106:Abstract no. 424.s
Harousseau JL, Attal M, Leleu X, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma. Haematologica. 2006;91:1498–1505.
Crawley C, Iacobelli S, Björkstrand B, et al. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood. 2007;109:3588–3594.
Badros A, Barlogie B, Siegel E, et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after non-myeloablative conditioning. J Clin Oncol. 2002;20:1295–1303.
Kroger N, Schwerdtfeger R, Kiehl M, et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood. 2002;100:755–760.
Maloney D, Molina A, Sahebi F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood. 2003;101:3447–3454.
Garban F, Attal M, Michallet M, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM 99-03 trial) with tandem autologous stem cell transplantation (IFM 99-04 trial) in high-risk de novo multiple myeloma. Blood. 2006;107:3474–3480.
Bruno B, Rotta M, Patriarca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med. 2007;356:1110–1120.
B G M Durie, J-L Harousseau, J S Miguel, at all. International uniform response criteria for multiple myeloma Leukemia (2006) 20, 1467–1473. doi: 10.1038/sj.leu.2404284